California Public Employees Retirement System Has $176.99 Million Position in Cencora, Inc. (NYSE:COR)

California Public Employees Retirement System reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,745 shares of the company's stock after selling 12,201 shares during the period. California Public Employees Retirement System owned approximately 0.41% of Cencora worth $176,991,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Cencora during the 4th quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC grew its holdings in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co acquired a new position in Cencora during the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co lifted its stake in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Ratings Changes

COR has been the subject of several research analyst reports. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Wells Fargo & Company upped their target price on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, JPMorgan Chase & Co. upped their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $280.20.

Remove Ads

Cencora Trading Down 3.5 %

Shares of Cencora stock traded down $10.07 during midday trading on Friday, reaching $279.29. The company had a trading volume of 4,404,535 shares, compared to its average volume of 1,469,415. The stock has a fifty day moving average price of $257.28 and a 200 day moving average price of $242.65. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $297.46. The firm has a market cap of $54.16 billion, a PE ratio of 39.73, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Insider Activity

In other news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the transaction, the chairman now directly owns 317,913 shares in the company, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock valued at $8,034,778 in the last ninety days. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.